Great announcement - Starpharma building more value into its IP. Smart move, ADCs are a big deal at the moment, and just getting bigger.
So, this new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021, whereby Merck (MSD) conducted a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.
Now, under this new 12 month agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.
Things are getting very interesting with biotech and ADCs, as reported below.
MERCK picks up another ADC agreement
Great announcement - Starpharma building more value into its IP....
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.44M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.5¢ | 10.5¢ | $132.0K | 1.162M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 535926 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.0¢ | 12.5¢ | 10.5¢ | 991112 | ||
| Last updated 15.53pm 03/05/2024 ? | |||||
| SPL (ASX) Chart |